Comparison of antibody response following the second dose of SARS-CoV-2 mRNA vaccine in elderly patients with late-stage chronic kidney disease

• Published in: Renal replacement therapy 2022-04, Vol.8 (1), p.13-13, Article 13
• Main Authors: Matsunami, Masatoshi, Suzuki, Tomo, Fukuda, Junko, Terao, Toshiki, Ukai, Kohei, Sugihara, Shinnosuke, Toishi, Takumi, Nagaoka, Kanako, Nakata, Mayumi, Ohara, Mamiko, Yashima, Jun, Kuji, Hiroshi, Matsue, Kosei
• Format: Article
• Language: English
• Subjects: Chronic kidney disease; COVID-19; Elderly patients; Hemodialysis; SARS-CoV-2 IgG antibody; Vaccination
• ISSN: 2059-1381; 2059-1381
• DOI: 10.1186/s41100-022-00402-x

Currently, it is unclear whether the progression of chronic kidney disease (CKD) could be an independent predictor of antibody response after administration of a COVID-19 vaccine. This study aimed to investigate the immune response to COVID-19 vaccination in patients with CKD stage G4 to G5 without renal replacement therapy and G5D using the recommended dose and schedule. This retrospective single-center cohort study evaluated immunogenicity regarding antibody response after COVID-19 vaccination in our hospital for late-stage CKD patients aged ≥ 60 years. We evaluated antibody responses in 48 patients with CKD G4, 35 patients with CKD G5, and 70 patients undergoing hemodialysis (HD; CKD G5D). After the second vaccination, anti-SARS-CoV-2-S (Spike) IgG levels were found to be positive (> 0.8 U/mL) in all CKD G4 and G5 patients (100%), and 69 of 70 HD patients (98.5%). The median (interquartile range [IQR] S-IgG level (Ab titers) was 358 [130.2-639.2], 218 [117-377], and 185.5 [95.1-323.5] U/mL in the CKD G4, G5, and HD groups, respectively. The median S-IgG levels were significantly lower in the HD group than in the CKD G4 group (